铅在体外血脑屏障模型跨膜转运机制的探讨
|
摘要
研究背景
铅是环境中普遍存在的污染物,在体内可以长期蓄积,对人体可以产生全身性多系统的损伤。它具有很强的神经亲和性,可在神经组织中蓄积,引起神经系统功能长期的不可逆的损害。近些年发现,铅的毒性作用没有安全阈值,即体内有铅便有毒。在人群中更为普遍的是慢性低水平铅中毒。虽然许多国家采取了一些降低环境铅污染的措施,但慢性铅中毒依然是现代城市的居民所面临的主要健康问题之一。
血脑屏障(BBB)是中枢神经系统的重要结构,它保证了中枢神经系统所需内环境的高度稳定,是中枢神经系统正常进行各项机能活动的基础;同时,BBB结构和/或功能的变化也是许多疾病病理生理变化的核心过程。铅不仅可以诱导脑微循环损伤改变脑血管内皮细胞的膜结构和紧密连接,使未成熟大脑的BBB发生渗漏,还可能通过脑内皮细胞的胞饮作用增强摄入大量的铅。近些年的研究显示,二价铁离子的跨膜转运体(divalent metal transporter 1, DMT1/NRAMP2/DCT1)也是铅的结合底物,并且铅与DMT1的亲和力比铁高。提示,在BBB铅可以竞争性抑制细胞铁的吸收来干扰细胞内铁的平衡,或者取代铁与铁结合蛋白结合来干扰这些蛋白质的功能。
本实验为了克服在体研究不能施加干预措施的局限性,通过对体外BBB模型的建立,进一步研究内皮细胞跨膜转运铅的具体机制以及与胞内铁平衡的关系,为阐明铅在血脑屏障转运的分子机制以及有效地采取防护措施提供新的理论依据和可行的途径。
研究目的
通过人脐静脉内皮细胞(ECV304)和小鼠胶质瘤细胞(C6)共培养建立体外BBB模型,从细胞水平上研究铅跨膜转运与细胞内铁含量变化的关系,以探索铅在BBB跨膜转运的途径及其可能的调控机制。
研究方法
1、用ECV304和C6细胞建立Transwell非接触式共培养体外BBB模型,测定跨内皮阻抗(Trans-endotheilal electrical resistance, TEER)和FITC-葡聚糖通过量来评价BBB的功能。
2、用钨舟原子吸收法测定铅在体外BBB模型转运的动力学特征;用免疫细胞染色法检测DMT1(IRE)蛋白在细胞内的定位;Western blot法检测细胞内DMT1(IRE)蛋白的表达水平;用DFX诱导细胞低铁来研究铅是否影响细胞内铁的平衡。
3、反义寡核苷酸转染干扰DMT1 mRNA和蛋白的表达;稳定高表达DMT1细胞的筛选;进一步用这两种细胞构建体外BBB模型以确定DMT1是否是铅进入内皮细胞的主要通路。
4、Western blot法检测细胞内IRP1和p-ERK1/2蛋白的表达水平;免疫共沉淀和免疫细胞化学双染法鉴定IRP1和p-ERK1/2蛋白之间是否存在相互作用;用ERK1/2通路的阻断剂(PD98059)研究IRP1和p-ERK1/2蛋白的相互作用与细胞中DMT1(IRE)蛋白表达调控的关系;钨舟原子吸收法测定PD98059对体外BBB模型转运铅的影响。
研究结果
1、ECV304和C6细胞非接触式共培养建立体外BBB模型ECV-304在C6胶质细胞的作用下,细胞间可以形成广泛的紧密连接复合体进而抑制外加电场下电流的跨内皮运动,产生了达232.5?cm2的TEER值;并且Papp均数在4、5、6d时均明显低于内皮细胞单独培养组,差异有显著性意义(p<0.05),说明我们建立了一种接近在体状态的体外血脑屏障模型。
2、铅在BBB模型中的转运具有主动转运的特点
铅的转运受pH值、温度、时间和剂量的影响。随着时间的增加,铅的转运量呈较为明显的上升趋势;并且铅的转运量随着铅剂量的增加而增加;在pH5.5的条件下转运铅的量显著高于pH7.4条件下的转运量;37oC时铅的转运量显著高于4oC时的转运量(p<0.05)。提示铅在BBB的转运是以主动转运为主。
3、铅诱导的跨膜转运增加是BBB通透性异常改变的主要原因
1μM和5μM Pb(NO3)2对体外BBB模型中ECV304细胞形成的TEER和Papp均没用显著的影响(p>0.05),对内皮细胞紧密连接蛋白claudin-1、ZO-1和occludin mRNA也没有明显的改变。铅可增加ECV 304细胞中DMT1(IRE)蛋白的表达,主要是显著增加了DMT1(IRE)在细胞膜上的表达量;不同时间染铅可以增加ECV304细胞中DMT1(IRE)蛋白表达,而DMT1(IRE)在细胞膜上表达的增加更为明显。结果提示,铅转运量的增加主要与跨膜转运异常密切相关。
4、铅诱导的跨膜转运异常增加与DMT1蛋白高表达及其膜定位密切相关
30μM FeCl3没有显著降低铅的转运(p>0.05);150μM FeCl3在4h和24h可以显著降低铅的转运(p<0.05)。铅和DFX都增加了细胞总蛋白和膜蛋白中DMT1(IRE)的表达;铁却可以降低铅诱导的DMT1(IRE)的表达。铅和铁均没有显著影响DMT1(IRE) mRNA的表达。用反义寡核苷酸转染以降低DMT1(IRE)蛋白的表达,可以降低BBB模型转运铅量,10h有显著性差异(p<0.05)。转染pcDNA3.0-DMT1重组质粒后,用G418筛选获得稳定转染细胞。稳定转染的ECV-304细胞与C6细胞共培养建立模型,可以增加铅的转运量;4h和24h有显著性差异(p<0.05)。以上结果提示,DMT1蛋白是铅跨膜转运的主要载体,细胞内铁稳态的失衡是铅转运增加的主要诱因之一。
5、IRP1与p-ERK1/2之间的相互作用可以负反馈调节DMT1蛋白的表达
铅在2h增加了细胞浆和细胞膜IRP1蛋白的表达,以后逐渐降低;铅还可以活化ERK1/2蛋白,而胞浆内ERK1/2的磷酸化却显著降低。铅和DFX都增加了细胞中IRP1和p-ERK1/2的表达;铁却可以抑制铅诱导的细胞浆IRP1和p-ERK1/2的高表达。共聚焦显微镜结果显示,细胞内IRP1与p-ERK1/2之间存在共定位,主要分布在细胞浆。铅和DFX都可以降低胞浆内IRP1与p-ERK1/2相互重叠的区域;铁却可以增加胞浆内IRP1与p-ERK1/2的相互重叠。免疫共沉淀结果显示,铅可增加相互作用的IRP1的表达,降低细胞浆内相互作用的p-ERK1/2。ERK阻断剂(PD98059)有增加总细胞DMT1(IRE)和胞浆IRP1蛋白的表达作用。加入PD98059,体外BBB模型的铅转运量增加,10h时有显著性差异(p<0.05)。以上结果提示,IRP1与p-ERK1/2之间的相互作用可以负反馈调节DMT1蛋白的表达。
研究结论
1、BBB通过DMT1(IRE)介导的跨膜转运增加铅的转运;
2、DMT1(IRE)蛋白是介导铅转运进入大脑的载体,并且DMT1(IRE)在细胞膜上的定位与铅转运增加密切相关;
3、DMT1蛋白的表达调控主要发生在转录后水平,是通过IRP/IRE调控模式调节DMT1(IRE) mRNA的翻译;
4、细胞内IRP1与p-ERK之间存在相互作用,可以调节IRP1的表达及功能;
5、在细胞水平上,ERK阻断剂(PD98059)可以上调DMT1蛋白的表达,促进BBB铅的转运。
Background
Lead is a persistent and common environmental contaminant. It accumulates in human body and exists for a long time. With its entry into the body, lead can cause toxic injury in erythrocytes, liver, renal cortex, aorta, brain, lungs, spleen, teeth, and bones. Studies of effects of lead on children have demonstrated the presence of irreversible neurological alterations at low concentrations. These findings demonstrate that, based on cellular and molecular evidence, there is no threshold for lead toxicity. A chronic, low-level intoxication of lead is more common in the general population. Although a variety of actions have been taken to decrease the use and distribution of lead in the environment, it remains a significant health hazard.
Due to its unique structure, the blood-brain barrier (BBB) is capable of limiting the penetration of a variety of substances from the blood into the brain. The BBB plays an important role in the homeostasis and is generally seen as a defence mechanism that protects the brain against various poisonous molecules that may traverse the BBB. The BBB has long been known to be a target for Pb toxicity. Under acute exposure to high levels of Pb, Pb-induced microvascular damage is prevalent with leaky microvessels, as characteristic opening of the interendothelial tight junctions and by enhanced pinocytotic activity seen in the damaged BBB. Studies show that lead is a substrate for the divalent metal transporter 1 (DMT1/ NRAMP2/ DCT1), and Pb2+ has a higher transport affinity than Fe2+. Data suggest that lead may interfere with iron homeostasis through pathways specific intended for iron or the substitute for Fe2+ to alter the function of iron-binding protein.
In the present study, we overcome the limitations of the in vivo research and try to explore the mechanism of the transcellular transportation of lead and the relationship between the transportation and cellular iron homeostasis. This study would offer the theoretical basis for elucidating the molecular mechanism of lead transport in the BBB and taking some effective measures to control lead toxicity. Aim:
The aim of the present study was, by co-culture ECV304 cells and C6 cells to establish BBB model in vitro, investigate the possible relationship between transcellular transport of lead and cellular iron homeostasis, and further explore the possible pathway of lead-induced transcellular transport and its regulatory mechanism. Methods:
1. A model of transwell was developed for the co-culture ECV304 cells and C6 cells to established BBB model in vitro, and the BBB restrictive characteristic was assessed by permeability of FITC-labeled dextran and measurement of transendotheilal electrical resistance (TEER).
2. The electrothermal atomization atomic absorption spectrometer was employed to measure the characteristic of lead transport kinetics, the intracellular distribution of DMT1 (IRE) protein was analysed by immunocytochemical method, and deferoximine (DFX), inducing iron deficiency to study the effects of lead on cellular iron homeostasis, was used.
3. Co-culture ECV304 cells transfected with antisense oligonucleotides to DMT1and pcDNA3.0-DMT1 vector respectively and C6 cells was used to establish BBB model in vitro respectively, and then the role of DMT1 (IRE) protein in lead trafficking was investigated.
4. The expression of IRP1 and p-ERK1/2 were analysed by western blot method, the interaction between IRP1 and p-ERK1/2 was identified by co-immunoprecipitation and immunocytochemical methods, the role of the interaction between IRP1 and p-ERK1/2 on the regulation of DMT1 (IRE) protein was investigated, and the effect of PD98059 on lead transportation in an in vitro BBB model was evaluated.
Results:
1. An in vitro BBB model by co-culture ECV304 cells and C6 cells was established.
Compare to the BBB with only ECV304 cells, TEER value (232.5?cm2) increased significantly in the co-culture. After 4 days of co-culture, apparent permeability coefficiency was significantly lower than that with the only ECV304 cells. Therefore, the in vitro BBB model by co-culture was suitable for the study of molecular changes of endothelial paracellular permeability and transendothelial transport.
2. Transportation of lead through the in vitro BBB had the characteristics of active transport.
Temperature, pH, time and dose all had effect on the transport of lead. With time passed, the transport of lead was significantly increased. The transport of lead was also significantly increased in high dose than that in low dose. Furthermore, the transport of lead was temperature-dependent and transport was higher at 37°C than at 4°C. Those results suggested that transport of lead might be characterized with active transport.
3. Abnormal changes of the BBB permeability was mainly caused by the enhanced transcellular transport of lead.
After 24 h, treatment of 1μM or 5μM lead could not significantly affect the TEER and apparent permeability coefficiency compared with the control (p>0.05). Treatment of 1μM or 5μM lead had no significant effect on claudin-1、ZO-1and occludin mRNA at four time points (2 h, 4 h, 10 h, 24 h). Treatment of lead enhanced the expression of DMT1 (IRE) protein, especially in the membrane fraction. At different time points, lead caused the increased expression of DMT1 (IRE), especially in the membrane. Results suggested that there was a correlation of enhanced transport of lead and transcellular transport of the BBB. 4. Lead-induced transcellular transport was related with the expression of DMT1 (IRE) protein and its localization in the membrane.
Treatment with 30μM FeCl3 had no significant influence on the transport of lead (p>0.05), while treatment with 150μM FeCl3 could decrease the transport of lead at 4 h and 24 h (p<0.05). Both lead and DFX increased the expression of DMT1 (IRE) protein in whole cell and membrane fraction. Iron inhibited the overexpression of DMT1 (IRE) induced with lead. Iron and/or lead did not affect the expression of DMT1 (IRE) mRNA. Antisense oligonucleotides (MA1) produced significant inhibition of the expression of DMT1 (IRE) protein. In an in vitro BBB model, MA1 treatment inhibited lead transport at all time points, and significant inhibition occurred only at 10 h (p<0.05). The recombined plasmids (pcDNA3.0-DMT1) were transfected into ECV304 cells. Cells were subjected to 200μg/ml of G418 antibiotic selection to obtain stable transfected cells. In an in vitro BBB model, stable transfected cells inhibited lead transport at all time points, and significant inhibition occurred only at 4 h and 10 h (p<0.05). There results suggested that DMT1 was the carrier of lead transport and changes of iron homeostasis were mainly caused by the enhanced lead transport.
5. The interaction between IRP1 and p-ERK1/2 negatively regulated the expression of DMT1 (IRE) protein.
The expression of IRP1 protein was increased by lead in the membrane and cytoplasm fractions at 2 h, and gradually declined with time passing. Compared to the control, lead significantly enhanced phosphorylation of ERK1/2 in the whole cell, but reduced phosphorylation of ERK1/2 in the cytoplasm fraction. Both lead and DFX increased the expressions of IRP1 and p-ERK1/2 proteins. Iron inhibited the overexpression of IRP1 and p-ERK1/2 induced by lead. Confocal microscopy was used to analyze ECV304 cells stained for IRP1 and p-ERK1/2 distribution. Results demonstrated that there was a cytoplasmic distribution of IRP1 as well as the co-localization with p-ERK1/2. Both lead and DFX could reduce the co-localization with p-ERK1/2, but iron increased the area of the co-localization. Results of co-immunoprecipitation showed that lead increased the interacted portion of IRP1, and decreased the interacted portion of p-ERK1/2. PD98059 could increase the expression of DMT1 (IRE) and cytoplasmic IRP1 proteins. In an in vitro BBB model, PD98059 treatment increased lead transport at all time points, and the significant increase occurred only at 10h (p<0.05). These results suggested that the interaction between IRP1 and p-ERK1/2 negatively regulated the expression of DMT1 (IRE) protein.
Conclusions:
1. DMT1 (IRE) is important in lead transcellular transport in an in vitro BBB model.
2. DMT1 (IRE) is a carrier of lead into brain, and it's localization in the membrane plays an important role in lead transcellular transport.
3. DMT1 (IRE) mRNA is regulated through stabilization by the IRE-IRP system.
4. There exists an interaction between IRP1 and p-ERK1/2 in ECV304 cells, regulating the expression and function of IRP1 protein.
5. ERK inhibitor, PD98059, increases an expression of DMT1, enhancing the lead transport in an in vitro BBB model.
铅是环境中普遍存在的污染物,在体内可以长期蓄积,对人体可以产生全身性多系统的损伤。它具有很强的神经亲和性,可在神经组织中蓄积,引起神经系统功能长期的不可逆的损害。近些年发现,铅的毒性作用没有安全阈值,即体内有铅便有毒。在人群中更为普遍的是慢性低水平铅中毒。虽然许多国家采取了一些降低环境铅污染的措施,但慢性铅中毒依然是现代城市的居民所面临的主要健康问题之一。
血脑屏障(BBB)是中枢神经系统的重要结构,它保证了中枢神经系统所需内环境的高度稳定,是中枢神经系统正常进行各项机能活动的基础;同时,BBB结构和/或功能的变化也是许多疾病病理生理变化的核心过程。铅不仅可以诱导脑微循环损伤改变脑血管内皮细胞的膜结构和紧密连接,使未成熟大脑的BBB发生渗漏,还可能通过脑内皮细胞的胞饮作用增强摄入大量的铅。近些年的研究显示,二价铁离子的跨膜转运体(divalent metal transporter 1, DMT1/NRAMP2/DCT1)也是铅的结合底物,并且铅与DMT1的亲和力比铁高。提示,在BBB铅可以竞争性抑制细胞铁的吸收来干扰细胞内铁的平衡,或者取代铁与铁结合蛋白结合来干扰这些蛋白质的功能。
本实验为了克服在体研究不能施加干预措施的局限性,通过对体外BBB模型的建立,进一步研究内皮细胞跨膜转运铅的具体机制以及与胞内铁平衡的关系,为阐明铅在血脑屏障转运的分子机制以及有效地采取防护措施提供新的理论依据和可行的途径。
研究目的
通过人脐静脉内皮细胞(ECV304)和小鼠胶质瘤细胞(C6)共培养建立体外BBB模型,从细胞水平上研究铅跨膜转运与细胞内铁含量变化的关系,以探索铅在BBB跨膜转运的途径及其可能的调控机制。
研究方法
1、用ECV304和C6细胞建立Transwell非接触式共培养体外BBB模型,测定跨内皮阻抗(Trans-endotheilal electrical resistance, TEER)和FITC-葡聚糖通过量来评价BBB的功能。
2、用钨舟原子吸收法测定铅在体外BBB模型转运的动力学特征;用免疫细胞染色法检测DMT1(IRE)蛋白在细胞内的定位;Western blot法检测细胞内DMT1(IRE)蛋白的表达水平;用DFX诱导细胞低铁来研究铅是否影响细胞内铁的平衡。
3、反义寡核苷酸转染干扰DMT1 mRNA和蛋白的表达;稳定高表达DMT1细胞的筛选;进一步用这两种细胞构建体外BBB模型以确定DMT1是否是铅进入内皮细胞的主要通路。
4、Western blot法检测细胞内IRP1和p-ERK1/2蛋白的表达水平;免疫共沉淀和免疫细胞化学双染法鉴定IRP1和p-ERK1/2蛋白之间是否存在相互作用;用ERK1/2通路的阻断剂(PD98059)研究IRP1和p-ERK1/2蛋白的相互作用与细胞中DMT1(IRE)蛋白表达调控的关系;钨舟原子吸收法测定PD98059对体外BBB模型转运铅的影响。
研究结果
1、ECV304和C6细胞非接触式共培养建立体外BBB模型ECV-304在C6胶质细胞的作用下,细胞间可以形成广泛的紧密连接复合体进而抑制外加电场下电流的跨内皮运动,产生了达232.5?cm2的TEER值;并且Papp均数在4、5、6d时均明显低于内皮细胞单独培养组,差异有显著性意义(p<0.05),说明我们建立了一种接近在体状态的体外血脑屏障模型。
2、铅在BBB模型中的转运具有主动转运的特点
铅的转运受pH值、温度、时间和剂量的影响。随着时间的增加,铅的转运量呈较为明显的上升趋势;并且铅的转运量随着铅剂量的增加而增加;在pH5.5的条件下转运铅的量显著高于pH7.4条件下的转运量;37oC时铅的转运量显著高于4oC时的转运量(p<0.05)。提示铅在BBB的转运是以主动转运为主。
3、铅诱导的跨膜转运增加是BBB通透性异常改变的主要原因
1μM和5μM Pb(NO3)2对体外BBB模型中ECV304细胞形成的TEER和Papp均没用显著的影响(p>0.05),对内皮细胞紧密连接蛋白claudin-1、ZO-1和occludin mRNA也没有明显的改变。铅可增加ECV 304细胞中DMT1(IRE)蛋白的表达,主要是显著增加了DMT1(IRE)在细胞膜上的表达量;不同时间染铅可以增加ECV304细胞中DMT1(IRE)蛋白表达,而DMT1(IRE)在细胞膜上表达的增加更为明显。结果提示,铅转运量的增加主要与跨膜转运异常密切相关。
4、铅诱导的跨膜转运异常增加与DMT1蛋白高表达及其膜定位密切相关
30μM FeCl3没有显著降低铅的转运(p>0.05);150μM FeCl3在4h和24h可以显著降低铅的转运(p<0.05)。铅和DFX都增加了细胞总蛋白和膜蛋白中DMT1(IRE)的表达;铁却可以降低铅诱导的DMT1(IRE)的表达。铅和铁均没有显著影响DMT1(IRE) mRNA的表达。用反义寡核苷酸转染以降低DMT1(IRE)蛋白的表达,可以降低BBB模型转运铅量,10h有显著性差异(p<0.05)。转染pcDNA3.0-DMT1重组质粒后,用G418筛选获得稳定转染细胞。稳定转染的ECV-304细胞与C6细胞共培养建立模型,可以增加铅的转运量;4h和24h有显著性差异(p<0.05)。以上结果提示,DMT1蛋白是铅跨膜转运的主要载体,细胞内铁稳态的失衡是铅转运增加的主要诱因之一。
5、IRP1与p-ERK1/2之间的相互作用可以负反馈调节DMT1蛋白的表达
铅在2h增加了细胞浆和细胞膜IRP1蛋白的表达,以后逐渐降低;铅还可以活化ERK1/2蛋白,而胞浆内ERK1/2的磷酸化却显著降低。铅和DFX都增加了细胞中IRP1和p-ERK1/2的表达;铁却可以抑制铅诱导的细胞浆IRP1和p-ERK1/2的高表达。共聚焦显微镜结果显示,细胞内IRP1与p-ERK1/2之间存在共定位,主要分布在细胞浆。铅和DFX都可以降低胞浆内IRP1与p-ERK1/2相互重叠的区域;铁却可以增加胞浆内IRP1与p-ERK1/2的相互重叠。免疫共沉淀结果显示,铅可增加相互作用的IRP1的表达,降低细胞浆内相互作用的p-ERK1/2。ERK阻断剂(PD98059)有增加总细胞DMT1(IRE)和胞浆IRP1蛋白的表达作用。加入PD98059,体外BBB模型的铅转运量增加,10h时有显著性差异(p<0.05)。以上结果提示,IRP1与p-ERK1/2之间的相互作用可以负反馈调节DMT1蛋白的表达。
研究结论
1、BBB通过DMT1(IRE)介导的跨膜转运增加铅的转运;
2、DMT1(IRE)蛋白是介导铅转运进入大脑的载体,并且DMT1(IRE)在细胞膜上的定位与铅转运增加密切相关;
3、DMT1蛋白的表达调控主要发生在转录后水平,是通过IRP/IRE调控模式调节DMT1(IRE) mRNA的翻译;
4、细胞内IRP1与p-ERK之间存在相互作用,可以调节IRP1的表达及功能;
5、在细胞水平上,ERK阻断剂(PD98059)可以上调DMT1蛋白的表达,促进BBB铅的转运。
Background
Lead is a persistent and common environmental contaminant. It accumulates in human body and exists for a long time. With its entry into the body, lead can cause toxic injury in erythrocytes, liver, renal cortex, aorta, brain, lungs, spleen, teeth, and bones. Studies of effects of lead on children have demonstrated the presence of irreversible neurological alterations at low concentrations. These findings demonstrate that, based on cellular and molecular evidence, there is no threshold for lead toxicity. A chronic, low-level intoxication of lead is more common in the general population. Although a variety of actions have been taken to decrease the use and distribution of lead in the environment, it remains a significant health hazard.
Due to its unique structure, the blood-brain barrier (BBB) is capable of limiting the penetration of a variety of substances from the blood into the brain. The BBB plays an important role in the homeostasis and is generally seen as a defence mechanism that protects the brain against various poisonous molecules that may traverse the BBB. The BBB has long been known to be a target for Pb toxicity. Under acute exposure to high levels of Pb, Pb-induced microvascular damage is prevalent with leaky microvessels, as characteristic opening of the interendothelial tight junctions and by enhanced pinocytotic activity seen in the damaged BBB. Studies show that lead is a substrate for the divalent metal transporter 1 (DMT1/ NRAMP2/ DCT1), and Pb2+ has a higher transport affinity than Fe2+. Data suggest that lead may interfere with iron homeostasis through pathways specific intended for iron or the substitute for Fe2+ to alter the function of iron-binding protein.
In the present study, we overcome the limitations of the in vivo research and try to explore the mechanism of the transcellular transportation of lead and the relationship between the transportation and cellular iron homeostasis. This study would offer the theoretical basis for elucidating the molecular mechanism of lead transport in the BBB and taking some effective measures to control lead toxicity. Aim:
The aim of the present study was, by co-culture ECV304 cells and C6 cells to establish BBB model in vitro, investigate the possible relationship between transcellular transport of lead and cellular iron homeostasis, and further explore the possible pathway of lead-induced transcellular transport and its regulatory mechanism. Methods:
1. A model of transwell was developed for the co-culture ECV304 cells and C6 cells to established BBB model in vitro, and the BBB restrictive characteristic was assessed by permeability of FITC-labeled dextran and measurement of transendotheilal electrical resistance (TEER).
2. The electrothermal atomization atomic absorption spectrometer was employed to measure the characteristic of lead transport kinetics, the intracellular distribution of DMT1 (IRE) protein was analysed by immunocytochemical method, and deferoximine (DFX), inducing iron deficiency to study the effects of lead on cellular iron homeostasis, was used.
3. Co-culture ECV304 cells transfected with antisense oligonucleotides to DMT1and pcDNA3.0-DMT1 vector respectively and C6 cells was used to establish BBB model in vitro respectively, and then the role of DMT1 (IRE) protein in lead trafficking was investigated.
4. The expression of IRP1 and p-ERK1/2 were analysed by western blot method, the interaction between IRP1 and p-ERK1/2 was identified by co-immunoprecipitation and immunocytochemical methods, the role of the interaction between IRP1 and p-ERK1/2 on the regulation of DMT1 (IRE) protein was investigated, and the effect of PD98059 on lead transportation in an in vitro BBB model was evaluated.
Results:
1. An in vitro BBB model by co-culture ECV304 cells and C6 cells was established.
Compare to the BBB with only ECV304 cells, TEER value (232.5?cm2) increased significantly in the co-culture. After 4 days of co-culture, apparent permeability coefficiency was significantly lower than that with the only ECV304 cells. Therefore, the in vitro BBB model by co-culture was suitable for the study of molecular changes of endothelial paracellular permeability and transendothelial transport.
2. Transportation of lead through the in vitro BBB had the characteristics of active transport.
Temperature, pH, time and dose all had effect on the transport of lead. With time passed, the transport of lead was significantly increased. The transport of lead was also significantly increased in high dose than that in low dose. Furthermore, the transport of lead was temperature-dependent and transport was higher at 37°C than at 4°C. Those results suggested that transport of lead might be characterized with active transport.
3. Abnormal changes of the BBB permeability was mainly caused by the enhanced transcellular transport of lead.
After 24 h, treatment of 1μM or 5μM lead could not significantly affect the TEER and apparent permeability coefficiency compared with the control (p>0.05). Treatment of 1μM or 5μM lead had no significant effect on claudin-1、ZO-1and occludin mRNA at four time points (2 h, 4 h, 10 h, 24 h). Treatment of lead enhanced the expression of DMT1 (IRE) protein, especially in the membrane fraction. At different time points, lead caused the increased expression of DMT1 (IRE), especially in the membrane. Results suggested that there was a correlation of enhanced transport of lead and transcellular transport of the BBB. 4. Lead-induced transcellular transport was related with the expression of DMT1 (IRE) protein and its localization in the membrane.
Treatment with 30μM FeCl3 had no significant influence on the transport of lead (p>0.05), while treatment with 150μM FeCl3 could decrease the transport of lead at 4 h and 24 h (p<0.05). Both lead and DFX increased the expression of DMT1 (IRE) protein in whole cell and membrane fraction. Iron inhibited the overexpression of DMT1 (IRE) induced with lead. Iron and/or lead did not affect the expression of DMT1 (IRE) mRNA. Antisense oligonucleotides (MA1) produced significant inhibition of the expression of DMT1 (IRE) protein. In an in vitro BBB model, MA1 treatment inhibited lead transport at all time points, and significant inhibition occurred only at 10 h (p<0.05). The recombined plasmids (pcDNA3.0-DMT1) were transfected into ECV304 cells. Cells were subjected to 200μg/ml of G418 antibiotic selection to obtain stable transfected cells. In an in vitro BBB model, stable transfected cells inhibited lead transport at all time points, and significant inhibition occurred only at 4 h and 10 h (p<0.05). There results suggested that DMT1 was the carrier of lead transport and changes of iron homeostasis were mainly caused by the enhanced lead transport.
5. The interaction between IRP1 and p-ERK1/2 negatively regulated the expression of DMT1 (IRE) protein.
The expression of IRP1 protein was increased by lead in the membrane and cytoplasm fractions at 2 h, and gradually declined with time passing. Compared to the control, lead significantly enhanced phosphorylation of ERK1/2 in the whole cell, but reduced phosphorylation of ERK1/2 in the cytoplasm fraction. Both lead and DFX increased the expressions of IRP1 and p-ERK1/2 proteins. Iron inhibited the overexpression of IRP1 and p-ERK1/2 induced by lead. Confocal microscopy was used to analyze ECV304 cells stained for IRP1 and p-ERK1/2 distribution. Results demonstrated that there was a cytoplasmic distribution of IRP1 as well as the co-localization with p-ERK1/2. Both lead and DFX could reduce the co-localization with p-ERK1/2, but iron increased the area of the co-localization. Results of co-immunoprecipitation showed that lead increased the interacted portion of IRP1, and decreased the interacted portion of p-ERK1/2. PD98059 could increase the expression of DMT1 (IRE) and cytoplasmic IRP1 proteins. In an in vitro BBB model, PD98059 treatment increased lead transport at all time points, and the significant increase occurred only at 10h (p<0.05). These results suggested that the interaction between IRP1 and p-ERK1/2 negatively regulated the expression of DMT1 (IRE) protein.
Conclusions:
1. DMT1 (IRE) is important in lead transcellular transport in an in vitro BBB model.
2. DMT1 (IRE) is a carrier of lead into brain, and it's localization in the membrane plays an important role in lead transcellular transport.
3. DMT1 (IRE) mRNA is regulated through stabilization by the IRE-IRP system.
4. There exists an interaction between IRP1 and p-ERK1/2 in ECV304 cells, regulating the expression and function of IRP1 protein.
5. ERK inhibitor, PD98059, increases an expression of DMT1, enhancing the lead transport in an in vitro BBB model.
引文
[1] Engelhardt B. Development of the blood-brain barrier. Cell Tissue Res. 2003; 314(1): 119-129.
[2] Akiyama H, Kondoh T, Kokunai T, Nagashima T, Saito N, Tamaki N. Blood-brain barrier formation of grafted human umbilical vein endothelial cells in athymic mouse brain. Brain Res. 2000; 858(1): 172-176.
[3] Imperatore C, Germanò A, d'Avella D, Tomasello F, Costa G. Effects of the radical scavenger AVS on behavioral and BBB changes after experimental subarachnoid hemorrhage. Life Sci. 2000; 66(9): 779-790.
[4] Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci. 2001; 24: 719-725.
[5] Kniesel U, Wolburg H. Tight junctions of the blood-brain barrier. Cell Mol Neurobiol. 2000; 20: 57-76.
[6] Vorbrodt AW, Dobrogowska DH. Molecular anatomy of interendothelial junctions in human blood-brain barrier microvessels. Folia Histochem Cytobiol. 2004, 421(2): 67-75.
[7] Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci. 2001; 24(12): 719-725.
[8] Vorbrodt AW, Dobrogowska DH. Molecular anatomy of intercellular junctions in brain endothelial and epithelial barriers: electron microscopist’s view. Brain Res Rev. 2003; 42: 221-242.
[9] Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. Claudin-1 and -2:novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol. 1998; 141(7): 1539-1550.
[10] Martìn-Padura I, Lostaglio S, Schneemann M, Williams L, Romano M, Fruscella P, Panzeri C, Stoppacciaro A, Ruco L, Villa A, Simmons D, Dejana E. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol. 1998; 142(1): 117-127.
[11] Fanning AS, Jameson BJ, Jesaitis LA, Anderson JM. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J Biol Chem. 1998; 273(45): 29745-29753.
[12] Haskins J, Gu L, Wittchen ES, Hibbard J, Stevenson BR. ZO-3, a novel member of the MAGUK protein family found at the tight junction, interacts with ZO-1 and occludin. J Cell Biol. 1998; 141(1): 199-208.
[13] Yap AS, Brieher WM, Gumbiner BM. Molecular and functional analysis of cadherin-based adherens junctions. Annu Rev Cell Dev Biol. 1997; 13: 119-146.
[14] Sedlakova R, Shivers RR, Del Maestro RF. Ultrastructure of the blood-brain barrier in the rabbit. J Submicronsc Cytol Pathol. 1999; 31:149-161.
[15] Fenstermacher J, Gross P, Sposito N, Acuff V, Pettersen S, Gruber K. Structural and functional variations in capillary systems within the brain. Ann NY Acad Sci. 1988; 529: 21-30.
[16] Abbott NJ. Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol Neurobiol. 2005; 25: 5-23.
[17] Oldendorf WH, Conford ME, Brown WJ. The large apparent workcapability of the blood-brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann Neurol. 1977;1: 409- 417.
[18] Pardridge WM. Molecular biology of the blood-brain barrier. Mol Biotechnol. 2005; 30: 57-70.
[19] Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005; 57: 173-185.
[20] Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006; 7: 41-53.
[21] Stewart PA, Wiley MJ. Developing nervous tissue induces formation of blood- brain barrier characteristics in invading endothelial cells: a study using quail: chick transplantation chimeras. Dev Biol. 1981, 84: 183-192.
[22] Janzer RC, Raf MC. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature. 1987, 325: 253-257.
[23] Bertossi M, Roncali L, Nico B, Ribatti D, Mancini L, Virgintino D, Fabiani G, Guidazzoli A. Perivascular astrocytes and endothelium in the development of the blood-brain barrier in the optic tectum of the chick embryo. Anat Embryol (Berl). 1993; 188(1): 21-29.
[24] Gumbleton M, Audus K. Progerss and limitations in the use of in vitro cell cultures to serve as a permeability screen for the Blood-Brain Barrier. Journal of Pharmaceutical Sciences. 2001; 90(11): 1681-169.
[25] Laterra J, Guerin C, Goldstein GW. Astrocytes induce neural microvascular endothelial cells to form capillary-like structures in vitro. J Cell Physiol. 1990; 144(2): 204-215.
[26] Hurwitz AA, Berman JW, Rashbaum WK, Lyman WD. Human fetal astrocytes induce the expression of blood-brain barrier specific proteins byautologous endothelial cells. Brain Res. 1993; 625(2): 238-243.
[27] Sobue K, Yamamoto N, Yoneda K, Hodgson ME, Yamashiro K, Tsuruoka N, Tsuda T, Katsuya H, Miura Y, Asai K, Kato T. Induction of blood-brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors. Neurosci Res. 1999; 35(2): 155-164.
[28] Yamagata K, Tagami M, Nara Y, Mitani M, Kubota A, Fujino H, Numano F, Kato T, Yamori Y. Astrocyte-conditioned medium induces blood-brain barrier properties in endothelial cells. Clin Exp Pharmacol Physiol. 1997; 24(9-10): 710-713.
[29] Rosenstein JM, Krum JM, Sternberger LA, Pulley MT, Sternberger NH. Immunocytochemical expression of the endothelial barrier antigen (EBA) during brain angiogenesis. Brain Res Dev Brain Res. 1992; 66(1): 47-54.
[30] Tagami M, Yamagata K, Fujino H, Kubota A, Nara Y, Yamori Y. Morphological differentiation of endothelial cells co-cultured with astrocytes on type-I or type-IV collagen. Cell Tissue Res. 1992; 268(2): 225-232.
[31] Tio S, Deenen M, Marani E. Astrocyte-mediated induction of alkaline phosphatase activity in human umbilical cord vein endothelium: an in vitro model. Eur J Morphol. 1990; 28(2-4): 289-300.
[32] Gardner TW, Lieth E, Khin SA, Barber AJ, Bonsall DJ, Lesher T, Rice K, Brennan WA Jr. Astrocytes increase barrier properties and ZO-1 expression in retinal vascular endothelial cells. Invest Ophthalmol Vis Sci. 1997; 38(11): 2423-2427.
[33] Hayashi Y, Nomura M, Yamagishi S, Harada S, Yamashita J, Yamamoto H. Induction of various blood-brain barrier properties in non-neural endothelial cells by close apposition to co-cultured astrocytes. Glia. 1997;19(1): 13-26.
[34] Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer’s disease. Prog Neurobiol. 2001; 64: 575-611.
[35] LeBleu VS, Macdonald B, Kalluri R. Structure and function of basement membranes. Exp Biol Med (Maywood). 2007; 232(9): 1121-1129.
[36] Aumailley M, Smyth N. The role of laminins in basement membrane function. J Anat. 1998; 193 ( Pt 1): 1-21.
[37] Bernoud N, Fenart L, Bénistant C, Pageaux JF, Dehouck MP, Molière P, Lagarde M, Cecchelli R, Lecerf J. Astrocytes are mainly responsible for the polyunsated fatty acid enrichment in blood-brain barrier endothelial cells in vitro. J Lipid Res. 1998; 39: 1816-1824.
[38] Gaillard PJ, Voorwinden LH, Nielsen JL, Ivanov A, Atsumi R, Engman H, Ringbom C, de Boer AG, Breimer DD. Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur J Pharm Sci. 2001; 12(3): 215-222.
[39] Fischer S, Wobben M, Kleinstück J, Renz D, Schaper W. Effect of astroglial cells on hypoxia-induced permeability in PBMEC cells. Am J Physiol Cell Physiol. 2000; 279(4): C935-944.
[40] Isobe I, Watanabe T, Yotsuyanagi T, Hazemoto N, Yamagata K, Ueki T, Nakanishi K, Asai K, Kato T. Astrocytic contributions to blood-brain barrier (BBB) formation by endothelial cells: a possible use of aortic endothelial cell for in vitro BBB model. Neurochem Int. 1996; 28(5-6): 523-533.
[41] Kuchler-Bopp S, Delaunoy JP, Artault JC, Zaepfel M, Dietrich JB. Astrocytes induce several blood-brain barrier properties in non-neuralendothelial cells. Neuroreport. 1999; 10(6): 1347-1353.
[42] Tan KH, Dobbie MS, Felix RA, Barrand MA, Hurst RD. A comparison of the induction of immortalized endothelial cell impermeability by astrocytes. Neuroreport. 2001; 12(7): 1329-1334.
[43] Scism JL, Laska DA, Horn JW, Gimple JL, Pratt SE, Shepard RL, Dantzig AH, Wrighton SA. Evaluation of an in vitro coculture model for the blood-brain barrier: comparison of human umbilical vein endothelial cells (ECV304) and rat glioma cells (C6) from two commercial sources. In Vitro Cell Dev Biol Anim. 1999; 35(10): 580-592.
[44] Hurst RD, Fritz IB. Properties of an immortalised vascular endothelial/glioma cell co-culture model of the blood-brain barrier. J Cell Physiol. 1996; 167(1): 81-88.
[45] Schroeter ML, Müller S, Lindenau J, Wiesner B, Hanisch UK, Wolf G, Blasig IE. Astrocytes induce manganese superoxide dismutase in brain capillary endothelial cells. Neuroreport. 2001; 12(11): 2513-2517.
[46] Gaillard PJ, van der Sandt IC, Voorwinden LH, Vu D, Nielsen JL, de Boer AG, Breimer DD. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharm Res. 2000; 17(10): 1198 -1205.
[47] Joó F. Endothelial cells of the brain and other organ systems: some similarities and differences. Prog Neurobiol. 1996; 48(3): 255-273.
[48] Franke H, Galla H, Beuckmann CT. Primary cultures of brain microvessel endothelial cells: a valid and flexible model to study drug transport through the blood-brain barrier in vitro. Brain Res Brain Res Protoc. 2000; 5(3): 248 -256.
[49] Godwin HA. The biological chemistry of lead. Curr Opin Chem Biol. 2001;5(2): 223-227.
[50] Greenwood NN, Earnshaw A. Chemistry of the elements. 2nd ed. London: Butterworth-Heinemann. 1997.
[51] Habermann E, Crowell K, Janicki P. Lead and other metals can substitute for Ca2+ in calmodulin. Arch Toxicol. 1983; 54: 61-70.
[52] Simons TJ. The affi nity of human erythrocyte porphobilinogen synthase for Zn2+ and Pb2+. Eur J Biochem. 1995; 234: 178-183.
[53] Kern M, Wisniewski M, Cabell L, Audesirk G. Inorganic lead and calcium interact positively in activation of calmodulin. Neurotoxicology. 2000; 21: 353-363.
[54] Ghering AB, Jenkins LM, Schenck BL, Deo S, Mayer RA, Pikaart MJ, Omichinski JG, Godwin HA. Spectroscopic and functional determination of the interaction of Pb2+ with GATA proteins. J Am Chem Soc. 2005; 127: 3751-3759.
[55] Atkins DS, Basha MR, Zawia NH. Intracellular signaling pathways involved in mediating the effects of lead on the transcription factor Sp1. Int J Dev Neurosci. 2003; 21(5): 235-244.
[56] ReddyG R,Z awiaN H.Lead exposure alters Egr-1 DNA-binding in the neonatal rat brain. Int J Dev Neurosci. 2000; 18(8): 791-795.
[57] Sharma R, Rensing C, Rosen BP, Mitra B. The ATP hydrolytic activity of purified ZntA, a Pb(II)/Cd(II)/Zn(II)-translocating ATPase from Escherichia coli. J Biol Chem. 2000; 275(6): 3873-3878.
[58] Erskine PT, Duke EM, Tickle IJ, Senior NM, Warren MJ, Cooper JB. MAD analyses of yeast 5-aminolaevulinate dehydratase: their use in structure determination and in defining the metal-binding sites. Acta Crystallogr D Biol Crystallogr. 2000; 56(Pt 4): 421-430.
[59] Bouton CM, Frelin LP, Forde CE, Arnold Godwin H, Pevsner J. Synaptotagmin I is a molecular target for lead. J Neurochem. 2001; 76(6): 1724-1735.
[60] Lewit-Bentley A, Réty S. EF-hand calcium-binding proteins. Curr Opin Struct Biol. 2000; 10(6): 637-643.
[61] Benes CH, Wu N, Elia AE, Dharia T, Cantley LC, Soltoff SP. The C2 domain of PKCdelta is a phosphotyrosine binding domain. Cell. 2005; 121(2): 271-280.
[62] Rizo J, Südhof TC. C2-domains, structure and function of a universal Ca2+- binding domain. J Biol Chem. 1998; 273(26): 15879-15882.
[63] Qian Y, Zheng Y, Ramos KS, Tiffany-Castiglioni E. GRP78 compartmentalized redistribution in Pb-treated glia: role of GRP78 in lead-induced oxidative stress. Neurotoxicology. 2005; 26(2): 267-275.
[64] Qian Y, Tiffany-Castiglioni E. Lead-induced endoplasmic reticulum (ER) stress responses in the nervous system. Neurochem Res. 2003; 28(1): 153-162.
[65] Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001; 107(1): 43-54.
[66] Garrick MD, Singleton ST, Vargas F, Kuo HC, Zhao L, Kn?pfel M, Davidson T, Costa M, Paradkar P, Roth JA, Garrick LM. DMT1: which metals does it transport? Biol Res. 2006; 39(1): 79-85.
[67] Adonaylo VN, Oteiza PI. Lead intoxication: antioxidant defenses andoxidative damage in rat brain. Toxicology. 1999; 135(2-3): 77-85.
[68] Flora GJ, Seth PK. Alterations in some membrane properties in rat brain following exposure to lead. Cytobios. 2000; 103(403): 103-109.
[69] Gurer H, Ercal N. Can antioxidants be beneficial in the treatment of lead poisoning? Free Radic Biol Med. 2000 Nov 15; 29(10): 927-945.
[70] Sandhir R, Julka D, Gill KD. Lipoperoxidative damage on lead exposure in rat brain and its implications on membrane bound enzymes. Pharmacol Toxicol. 1994; 74(2): 66-71.
[71] Aykin-Burns N, Franklin EA, Ercal N. Effects of N-acetylcysteine on lead-exposed PC-12 cells. Arch Environ Contam Toxicol. 2005; 49(1): 119-123.
[72] Vaziri ND, Lin CY, Farmand F, Sindhu RK. Superoxide dismutase, catalase, glutathione peroxidase and NADPH oxidase in lead-induced hypertension.Kidney Int. 2003; 63(1): 186-194.
[73] Goyer RA. Transplacental transport of lead. Environ Health Perspest. 1990; 89: 101-105.
[74] 阮素云, 顾祖维, 杨勇骥. 采用能谱法研究铅对大鼠BBB的通透性. 中华预防医学杂志. 1999; 33(2): 107-109.
[75] Wang Q, Luo W, Zheng W, Liu Y, Xu H, Zheng G, Dai Z, Zhang W, Chen Y, Chen J. Iron supplement prevents lead-induced disruption of the blood-brain barrier during rat development. Toxicol appl pharmacol 2007; 219(1): 33-41.
[76] Garza A, Vega R, Soto E. Cellular mechanisms of lead neurotoxicity. Med Sci Monit. 2006; 12(3): RA57-65.
[77] Yan D, Wang L, Ma FL, Deng H, Liu J, Li C, Wang H, Chen J, Tang JL, Ruan DY. Developmental exposure to lead causes inherent changes onvoltage-gated sodium channels in rat hippocampal CA1 neurons. Neuroscience. 2008; [Epub ahead of print].
[78] Soodi M, Sharifzadeh M, Naghdi N, Ostad N, Abdollahi M, Roghani A. Systemic and developmental exposure to lead causes spatial memory deficits and a reduction in COX-2 immunoreactivity in the hippocampus of male rats. J Neurosci Res. 2007; 85(14): 3183-3192.
[79] Gilbert ME, Lasley SM. Developmental lead (Pb) exposure reduces the ability of the NMDA antagonist MK-801 to suppress long-term potentiation (LTP) in the rat dentate gyrus, in vivo. Neurotoxicol Teratol. 2007; 29(3): 385-393.
[80] Gilbert ME, Kelly ME, Samsam TE, Goodman JH. Chronic developmental lead exposure reduces neurogenesis in adult rat hippocampus but does not impair spatial learning. Toxicol Sci. 2005; 86(2): 365-374.
[81] Grandjean P, Landrigan PJ. Developmental neurotoxicity of industrial chemicals. Lancet. 2006 Dec 16;368(9553):2167-78.
[82] Pollitt E. Fuctional significance of the covariance between protein energy malnutrition and iron deficiency anemia. J Nutr. 1995; 125: 2272.
[83] Gerlach, M, Benshachar D, Riederer P, Youdim MB. Altered brain metabolism of iron as a cause of neurodegenerative diseases. J Neurochem. 1994; 63: 793-807.
[84] Qian ZM, Pu YM, Tang PL, Wang Q. Transferrin-bound iron uptake by the cultured cerebellar granule cells. Neurosci Lett. 1998; 251: 9-12.
[85] Beard JL, Chen, Q, Connor J, Jones BC. Altered monamine metabolism in caudate-putamen of iron-deficeint rats. Pharmacol Biochem Behav. 1994; 48: 621-624.
[86] Bartlett WP, Li XS, Connor JR. Expression of transferrin mRNA in theCNS of normal and jimpy mice. J Neurochem. 1991; 57: 318-322.
[87] Taylor EM, Morgan EH. Developmental changes in transferrin and iron uptake by the brain in the rat. Dev Brain Res. 1990; 55: 35 -42.
[88] Connor JR, Boeshore KL, Benkovic SA, Menzies SL. Isoforms of ferritin have a specific cellular distribution in the brain. J Neurosci Res . 1994; 37: 461-465.
[89] Dallman PR, Spirito RA. Brain iron in the rat: extremely slow turnover in normal. rats may explain the long-lasting effects of early iron deficiency. J Nutr. 1977; 107:1075-1081.
[90] Samaniego F, Chin J, Iwai K, Rouault TA, Klausner RD. Molecular characterization of a second iron-responsive element binding protein,iron regulatory protein 2 structure,function,and post-translational regulation. J Biol Chem. 1994; 269(49): 30904.
[91] Guo B, Yu Y, Leibold EA. Iron regulates cytoplasmic levels of a novel iron-responsive element-binding protein without aconitase activity. J. Biol. Chem. 1994; 269: 24252-24260.
[92] Henderson BR, Seiser C, Kuhn LC. Characterization of a second RNA- binding protein in rodents with specificity for iron-responsive elements. J Biol Chem. 1993; 268: 27327-27334.
[93] Samaniego F, Chin J, Iwai K, Rouault TA, Klausner RD. Molecular characterization of a second iron-responsive element binding protein, iron regulatory protein 2. Structure, function, and posttranslational regulation. J Biol Chem. 1994; 269: 30904-30910.
[94] Schalinske KL, Blemings KP, Steffen DW, Chen OS, Eisenstein RS. Iron regulatory protein 1 is not required for the modulation of ferritin and transferrin receptor expression by iron in a murine pro-B lymphocyte cellline. Proc Natl Acad Sci U S A. 1997; 94(20): 10681-10686.
[95] Crichton RR, Wilmet S, Legssyer R, Ward RJ. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J Inorg Biochem. 2002; 91: 9-18.
[96] Goessling LS, Mascotti DP, Thach RE. Involvement of heme in the degradation of iron-regulatory protein 2. J Biol Chem. 1998; 273(20): 12555- 12557.
[97] Ishikawa H, Kato M, Hori H, Ishimori K, Kirisako T, Tokunaga F, Iwai K. Involvement of heme regulatory motif in heme-mediated ubiquitination and degradation of IRP2. Mol Cell. 2005; 19(2): 171-181.
[98] Wang J, Chen G, Muckenthaler M, Galy B, Hentze MW, Pantopoulos K. Iron-mediated degradation of IRP2, an unexpected pathway involving a 2-oxoglutarate-dependent oxygenase activity. Mol Cell Biol. 2004; 24: 954- 965.
[99] Eisenstein RS. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu Rev Nutr. 2000; 20: 627-662.
[100] Haile DJ, Rouault TA, Harford JB, Kennedy MC, Blondin GA, Beinert H, Klausner RD. Cellular regulation of the iron-responsive element binding protein: disassembly of the cubane iron-sulfur cluster results in high-affinity RNA binding. Proc Natl Acad Sci U S A. 1992; 89(24): 11735-11739.
[101] Rouault TA, Haile DJ, Downey WE, Philpott CC, Tang C, Samaniego F, Chin J, Paul I, Orloff D, Harford JB, Klausner RD. An iron-sulfur cluster plays a novel regulatory role in the iron-responsive element binding protein. Biometals. 1992; 5(3): 131-140.
[102] Fillebeen C, Caltagirone A, Martelli A, Moulis JM, Pantopoulos K. IRP1Ser-711 is a phosphorylation site, critical for regulation of RNA-binding and aconitase activities. Biochem J. 2005; 388(Pt 1): 143-150.
[103] Brown NM, Anderson SA, Steffen DW, Carpenter TB, Kennedy MC, Walden WE, Eisenstein RS. Novel role of phosphorylation in Fe-S cluster stability revealed by phosphomimetic mutations at Ser-138 of iron regulatory protein 1. TProc Natl Acad Sci U S A. 1998; 95(26): 15235-15240.
[104] Bannon D I, Portnoy ME, Olivi L, Uptake of lead and iron by divalent metal transporter 1 in yeast and mammalian cells. Biochem Biophys Res Commun. 2002; 295(4): 978-984.
[105] Siddappa AJ, Rao RB, Wobken JD, Casperson K, Leibold EA, Connor JR, Georgieff MK. Iron Deficiency Alters Iron Regulatory Protein and Iron Transport Protein Expression in the Perinatal Rat Brain. Pediatr Res. 2003; 53(5): 800-807.
[106] Chen H, Davidson T, Singleton S, Garrick MD, Costa M. Nickel decreases cellular iron level and converts cytosolic aconitase to iron-regulatory protein 1 in A549 cells. Toxicol Appl Pharmacol. 2005; 206(3): 275-287.
[107] Parton RG, Joggerst B, Simons K. Regulated internalization of caveolae. J Cell Biol. 1994; 127: 1199-1215.
[108] Cordova FM, Rodrigues AL, Giacomelli MB, Oliveira CS, Posser T, Dunkley PR, Leal RB. Lead stimulates ERK1/2 and p38MAPK phosphorylation in the hippocampus of immature rats. Brain Res. 2004; 998(1): 65-72.
[109] Jovanovic JN, Czernik AJ, Fienberg AA, Greengard P, Sihra TS. Synapsins as mediators of BDNF-enhanced neurotransmitter release. Nat Neurosci. 2000; 3: 323-329.
[110] Matsubara M, Kusubata M, Ishiguro K, Uchida T, Titani K, Taniguchi H. Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions. J Biol Chem. 1996; 271(35): 21108-21113.
[111] Bhat RV, Engber TM, Finn JP, Koury EJ, Contreras PC, Miller MS, Dionne CA, Walton KM. Region-specific targets of p42/p44 MAPK signaling in rat brain. J Neurochem. 1998; 70: 558-571.
[112] Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. J Neurochem, 2000, 74: 1587-1595.
[113] Atkins CM, Yon M, Groome NP, Sweatt JD. Regulation of myelin basic protein phosphorylation by mitogen-activated protein kinase during increased action potential firing in the hippocampus. J Neurochem. 1999; 73(3): 1090-1097.
[114] Basuroy S, Seth A, Elias B, Naren AP, Rao R. MAP kinase interacts with occludin and mediates EGF-induced prevention of tight junction disruption by hydrogen peroxide. Biochem J. 2006; 393: 69-77.
[115] 黄强. 胶质瘤. 第二版. 北京: 中国科学技术出版社. 2000. 84.
[116] Reiche1 A, Begley DJ, Abboet NT. An overview of in vitro techniques for BBB studies in nagsed the BBB biology and research. Protocols Humana press. New Jersey. 2003, 307-324.
[117] Gee JR, Keller JN. Astrocys: regulation of brain homeostasis via apolipoprotein E. Int J Biochem Cell Biol. 2005; 37(6): 1145-1150.
[118] Willis LL, Nolan LL, Reith SN. Focal astrocyte loss is followed bymicrovascular damage, with subsequent repair of the BBB in the apparent absence of direct astrocytic contact. Glia. 2004; 45(4): 325-337.
[119] Hamms S, Dehouck B, Kraus J. Astrocyte mediated modulation of BBB permeability dose not correlate with a loss of TJ proteins from the cellular contacts. Cell Tissue Res. 2004; 315(2): 157-166.
[120] Tahti H, Nevala H, Toimela T. Astrocyte and endothelial three-dimensional refining in vitro neurotoxicity testing-the development of BBB models. Altern Lab Anim. 2003; 31(3): 273-276.
[121] Jeliazkova-Mecheva VV, Bobilya DJ. A porcine astrocyte/endothelial cell co-culture model of the BBB. Brain Res Protoc. 2003; 12(2): 9-18.
[122] Kido Y, Tamai I, Nakanish T. Evaluation of BBB transporter by co-culture of brain capillary endothelial cells with astrocyte. Metab Pharmacokinee. 2002; 17(1): 34-41.
[123] Schiera G, Sala S, Gallo A, Raffa MP, Pitarresi GL, Savettieri G, Di Liegro I. Permeability properties of a three-cell type in vitro model of BBB. J Cell Mol Med. 2005; 9(2): 373-379.
[124] Fitsanakis VA, Piccola G, Aschner JL. Manganese transport by rat brain endothelial cell-based transwell model in the presence of astrocyte conditioned media. J Neurosci Res. 2005; 15(2): 235-243.
[125] Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: overview: structure, regulation and clinical implications. Neurobiol Dis. 2004; 16(1): 1-13.
[126] Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat. 2002; 200: 629-638.
[127] Ma SH, Lepak LA, Hussain RJ, Shain W, Shuler ML. An endothelial and astrocyte co-culture model of the blood-brain barrier utilizing an ultra-thin,nanofabricated silicon nitride membrane. Lab Chip. 2005; 5(1): 74-85.
[128] Struzynska L, Walski M, Gadamski R, Dabrowska-Bouta B, Rafalowska U. Lead-induced abnormalities in blood–brain barrier permeability in experimental chronic toxicity. Mol Chem Neuropathol. 1997; 31: 207-224.
[129] Hossain MA, Russell JC, Miknyoczki S, Ruggeri B, Lal B, Laterra J.Vascular endothelial growth factor mediates vasogenic edema in acute lead encephalopathy. Ann Neurol. 2004; 55(5): 660-667.
[130] Dingwall-Fordyce I, Lane RE. A follow-up study of lead workers. Br J Ind Med. 1963; 20: 313.
[131] Dill KA. Dominant forces in protein folding. Biochemistry. 1990, 29(31): 7133-7155.
[132] Goto Y, Hagihara Y, Hamada D, Hoshino M, Nishii I. Acid-induced unfolding and refolding transitions of cytochrome c: a three-state mechanism in H2O and D2O. Biochemistry. 1993; 32(44): 11878-11885.
[133] 张培林. 神经解剖学[M]. 北京: 人民卫生出版社. 1995; 506-510.
[134] Mims MP, Prchal JT. Divalent metal transporter 1. Hematology. 2005; 10(4): 339-345.
[135] Mckie AT, Barrow D, Latunde-Dada GO, et al. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science. 2001; 291(5509): 1755-1759.
[136] Zheng W, Perry DF, Nelson DL, Aposhian HV. Protection of cerebrospinal fluid against toxic metals by the choroid plexus. FASEB J. 1991;5: 2188- 2193.
[137] Muldoon SB, Cauley JA, Kuller LH, Morrow L, Needleman HL, Scott J, Hooper FJ. Effects of blood lead levels on cognitive function of older women. Neuroepidemiology. 1996; 15: 62-72.
[138] Schwartz BS, Stewart WF, Bolla KI, Simon PD, Bandeen-Roche K, Gordon PB, Links JM, Todd AC. Past adult lead exposure is associated with longitudinal decline in cognitive function. Neurology. 2000; 55: 1144-1150.
[139] Stollery BT. Reaction time changes in workers exposed to lead. Neurotoxicol Teratol. 1996; 18: 477-483.
[140] Dyatlov VA, Platoshin AV, Lawrence DA, Carpenter DO. Lead potentiates cytokine- and glutamate-mediated increases in permeability of the blood-brain barrier. Neurotoxicology. 1998; 19: 283-291.
[141] Sundstrom R, Muntzing K, Kalimo H, Sourander P. Changes in the integrity of the blood-brain barrier in suckling rats with low dose lead encephalopathy. Acta Neuropathol. 1985; 68: 1-9.
[142] Bradbury MW, Deane R. Permeability of the blood-brain barrier to lead. Neurotoxicol. 1993; 14: 131-136.
[143] Kerper LE, Hinkle PM. Lead uptake in brain capillary endothelial cells: activation by calcium store depletion. Toxicol Appl Pharmacol. 1997; 146: 127-133.
[144] Press MF. Lead-induced permeability changes in immature vessels of the developing cerebellar microcirculation. Acta. Neuropathol. 1985; 67: 86-95.
[145] Press MF. Lead encephalopathy in neonatal Long-Evans rats: morphologic studies. J Neuropathol Exp Neurol. 1977; 36: 169-193.
[146] Nusrat A, Parkos CA, Verkade P, Foley CS, Liang TW, Innis-Whitehouse W, Eastburn KK, Madara JL. Tight junctions are membrane microdomains. J Cell Sci. 2000; 113 ( Pt 10): 1771-1781.
[147] Witt KA, Mark KS, Hom S, Davis TP. Effects of hypoxia-reoxygenation on rat blood-brain barrier permeability and tight junctional protein expression.Am J Physiol Heart Circ Physiol. 2003; 285(6): H2820-2831.
[148] Shi LZ, Zheng W. Early lead exposure increases the leakage of the blood-erebrospinal fluid barrier, in vitro. Hum Exp Toxicol. 2007; 26: 159-167.
[149] Shindo M, Torimoto Y, Saito H, et al. Functional role of DMT1 in transferring-dependent iron uptake by human hepatocyte and hepatocellular carcinoma cell, HLF. Hepatol Res. 2006; 35(3): 152-162.
[150] Roth JA, Horbinski C, Feng L, Dolan KG, Higgins D, Garrick MD. Roth JA, Orbinski C, Feng L, et al. Differential localization of divalent metal transporter 1 with and without iron response element in rat PC12 and sympathetic neuronal cells. Neuroscience. 2000; 20(20): 7595-7601.
[151] Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, Hediger MA. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature. 1997; 388(6641): 482-488.
[152] Ke Y, Chang YZ, Duan XL, et al. Age-dependent and iron-independent expression of two mRNA isoforms of divalent metal transporter 1 in rat brain. Neurobiol Aging. 2005; 26(5): 739-748.
[153] Arredondo M, Mu?oz P, Mura CV, Nù?ez MT. DMT1, a physiologically relevant apical Cu1+ transporter of intestinal cells. Am J Physiol Cell Physiol. 2003; 284(6): C1525-1530.
[154] Ong WY, He X, Chua LH, Ong CN. Increased uptake of divalent metals lead and cadmium into the brain after kainite-induced neuronal injury. Exp Brain Res. 2006; 173(3): 468-474.
[155] Kwong WT, Friello P, Semba RD. Interactions between iron deficiency and lead poisoning: epidemiology and pathogenesis. Sci Total Environ. 2004;330(1-3): 21-37.
[156] Pi?ero DJ, Li N, Hu J, Beard JL, Connor JR. The intracellular location of iron regulatory proteins is altered as a function of iron status in cell cultures and rat brain. J Nutr. 2001; 131(11): 2831-2836.
[157] Tong WH, Rouault T. Distinct iron-sulfur cluster assembly complexes exist in the cytosol and mitochondria of human cells. EMBO J. 2000; 19(21): 5692-5700.
[158] Roy A, Solodovnikova N, Nicholson T, Antholine W, Walden WE. A novel eukaryotic factor for cytosolic Fe-S cluster assembly. EMBO J. 2003; 22(18): 4826-4835.
[159] Wang Q, Luo W, Zhang W, Dai Z, Chen Y, Chen J. Iron supplementation protects against lead-induced apoptosis through MAPK pathway in weanling rat cortex. Neurotoxicology. 2007; 28(4): 850-859.
[160] Eisenstein RS, Tuazon PT, Schalinske KL, Anderson SA, Traugh JA. Iron-responsive element-binding protein. Phosphorylation by protein kinase C. J Biol Chem. 1993; 268(36): 27363-27370.
[161] Schalinske KL, Eisenstein RS. Phosphorylation and activation of both iron regulatory proteins 1 and 2 in HL-60 cells. J Biol Chem. 1996; 271(12): 7168-7176.
[162] Patton SM, Pi?ero DJ, Surguladze N, Beard J, Connor JR. Subcellular localization of iron regulatory proteins to Golgi and ER membranes. J Cell Sci. 2005; 118(Pt 19): 4365-4373.
[2] Akiyama H, Kondoh T, Kokunai T, Nagashima T, Saito N, Tamaki N. Blood-brain barrier formation of grafted human umbilical vein endothelial cells in athymic mouse brain. Brain Res. 2000; 858(1): 172-176.
[3] Imperatore C, Germanò A, d'Avella D, Tomasello F, Costa G. Effects of the radical scavenger AVS on behavioral and BBB changes after experimental subarachnoid hemorrhage. Life Sci. 2000; 66(9): 779-790.
[4] Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci. 2001; 24: 719-725.
[5] Kniesel U, Wolburg H. Tight junctions of the blood-brain barrier. Cell Mol Neurobiol. 2000; 20: 57-76.
[6] Vorbrodt AW, Dobrogowska DH. Molecular anatomy of interendothelial junctions in human blood-brain barrier microvessels. Folia Histochem Cytobiol. 2004, 421(2): 67-75.
[7] Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci. 2001; 24(12): 719-725.
[8] Vorbrodt AW, Dobrogowska DH. Molecular anatomy of intercellular junctions in brain endothelial and epithelial barriers: electron microscopist’s view. Brain Res Rev. 2003; 42: 221-242.
[9] Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. Claudin-1 and -2:novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol. 1998; 141(7): 1539-1550.
[10] Martìn-Padura I, Lostaglio S, Schneemann M, Williams L, Romano M, Fruscella P, Panzeri C, Stoppacciaro A, Ruco L, Villa A, Simmons D, Dejana E. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol. 1998; 142(1): 117-127.
[11] Fanning AS, Jameson BJ, Jesaitis LA, Anderson JM. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J Biol Chem. 1998; 273(45): 29745-29753.
[12] Haskins J, Gu L, Wittchen ES, Hibbard J, Stevenson BR. ZO-3, a novel member of the MAGUK protein family found at the tight junction, interacts with ZO-1 and occludin. J Cell Biol. 1998; 141(1): 199-208.
[13] Yap AS, Brieher WM, Gumbiner BM. Molecular and functional analysis of cadherin-based adherens junctions. Annu Rev Cell Dev Biol. 1997; 13: 119-146.
[14] Sedlakova R, Shivers RR, Del Maestro RF. Ultrastructure of the blood-brain barrier in the rabbit. J Submicronsc Cytol Pathol. 1999; 31:149-161.
[15] Fenstermacher J, Gross P, Sposito N, Acuff V, Pettersen S, Gruber K. Structural and functional variations in capillary systems within the brain. Ann NY Acad Sci. 1988; 529: 21-30.
[16] Abbott NJ. Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol Neurobiol. 2005; 25: 5-23.
[17] Oldendorf WH, Conford ME, Brown WJ. The large apparent workcapability of the blood-brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann Neurol. 1977;1: 409- 417.
[18] Pardridge WM. Molecular biology of the blood-brain barrier. Mol Biotechnol. 2005; 30: 57-70.
[19] Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005; 57: 173-185.
[20] Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006; 7: 41-53.
[21] Stewart PA, Wiley MJ. Developing nervous tissue induces formation of blood- brain barrier characteristics in invading endothelial cells: a study using quail: chick transplantation chimeras. Dev Biol. 1981, 84: 183-192.
[22] Janzer RC, Raf MC. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature. 1987, 325: 253-257.
[23] Bertossi M, Roncali L, Nico B, Ribatti D, Mancini L, Virgintino D, Fabiani G, Guidazzoli A. Perivascular astrocytes and endothelium in the development of the blood-brain barrier in the optic tectum of the chick embryo. Anat Embryol (Berl). 1993; 188(1): 21-29.
[24] Gumbleton M, Audus K. Progerss and limitations in the use of in vitro cell cultures to serve as a permeability screen for the Blood-Brain Barrier. Journal of Pharmaceutical Sciences. 2001; 90(11): 1681-169.
[25] Laterra J, Guerin C, Goldstein GW. Astrocytes induce neural microvascular endothelial cells to form capillary-like structures in vitro. J Cell Physiol. 1990; 144(2): 204-215.
[26] Hurwitz AA, Berman JW, Rashbaum WK, Lyman WD. Human fetal astrocytes induce the expression of blood-brain barrier specific proteins byautologous endothelial cells. Brain Res. 1993; 625(2): 238-243.
[27] Sobue K, Yamamoto N, Yoneda K, Hodgson ME, Yamashiro K, Tsuruoka N, Tsuda T, Katsuya H, Miura Y, Asai K, Kato T. Induction of blood-brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors. Neurosci Res. 1999; 35(2): 155-164.
[28] Yamagata K, Tagami M, Nara Y, Mitani M, Kubota A, Fujino H, Numano F, Kato T, Yamori Y. Astrocyte-conditioned medium induces blood-brain barrier properties in endothelial cells. Clin Exp Pharmacol Physiol. 1997; 24(9-10): 710-713.
[29] Rosenstein JM, Krum JM, Sternberger LA, Pulley MT, Sternberger NH. Immunocytochemical expression of the endothelial barrier antigen (EBA) during brain angiogenesis. Brain Res Dev Brain Res. 1992; 66(1): 47-54.
[30] Tagami M, Yamagata K, Fujino H, Kubota A, Nara Y, Yamori Y. Morphological differentiation of endothelial cells co-cultured with astrocytes on type-I or type-IV collagen. Cell Tissue Res. 1992; 268(2): 225-232.
[31] Tio S, Deenen M, Marani E. Astrocyte-mediated induction of alkaline phosphatase activity in human umbilical cord vein endothelium: an in vitro model. Eur J Morphol. 1990; 28(2-4): 289-300.
[32] Gardner TW, Lieth E, Khin SA, Barber AJ, Bonsall DJ, Lesher T, Rice K, Brennan WA Jr. Astrocytes increase barrier properties and ZO-1 expression in retinal vascular endothelial cells. Invest Ophthalmol Vis Sci. 1997; 38(11): 2423-2427.
[33] Hayashi Y, Nomura M, Yamagishi S, Harada S, Yamashita J, Yamamoto H. Induction of various blood-brain barrier properties in non-neural endothelial cells by close apposition to co-cultured astrocytes. Glia. 1997;19(1): 13-26.
[34] Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer’s disease. Prog Neurobiol. 2001; 64: 575-611.
[35] LeBleu VS, Macdonald B, Kalluri R. Structure and function of basement membranes. Exp Biol Med (Maywood). 2007; 232(9): 1121-1129.
[36] Aumailley M, Smyth N. The role of laminins in basement membrane function. J Anat. 1998; 193 ( Pt 1): 1-21.
[37] Bernoud N, Fenart L, Bénistant C, Pageaux JF, Dehouck MP, Molière P, Lagarde M, Cecchelli R, Lecerf J. Astrocytes are mainly responsible for the polyunsated fatty acid enrichment in blood-brain barrier endothelial cells in vitro. J Lipid Res. 1998; 39: 1816-1824.
[38] Gaillard PJ, Voorwinden LH, Nielsen JL, Ivanov A, Atsumi R, Engman H, Ringbom C, de Boer AG, Breimer DD. Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur J Pharm Sci. 2001; 12(3): 215-222.
[39] Fischer S, Wobben M, Kleinstück J, Renz D, Schaper W. Effect of astroglial cells on hypoxia-induced permeability in PBMEC cells. Am J Physiol Cell Physiol. 2000; 279(4): C935-944.
[40] Isobe I, Watanabe T, Yotsuyanagi T, Hazemoto N, Yamagata K, Ueki T, Nakanishi K, Asai K, Kato T. Astrocytic contributions to blood-brain barrier (BBB) formation by endothelial cells: a possible use of aortic endothelial cell for in vitro BBB model. Neurochem Int. 1996; 28(5-6): 523-533.
[41] Kuchler-Bopp S, Delaunoy JP, Artault JC, Zaepfel M, Dietrich JB. Astrocytes induce several blood-brain barrier properties in non-neuralendothelial cells. Neuroreport. 1999; 10(6): 1347-1353.
[42] Tan KH, Dobbie MS, Felix RA, Barrand MA, Hurst RD. A comparison of the induction of immortalized endothelial cell impermeability by astrocytes. Neuroreport. 2001; 12(7): 1329-1334.
[43] Scism JL, Laska DA, Horn JW, Gimple JL, Pratt SE, Shepard RL, Dantzig AH, Wrighton SA. Evaluation of an in vitro coculture model for the blood-brain barrier: comparison of human umbilical vein endothelial cells (ECV304) and rat glioma cells (C6) from two commercial sources. In Vitro Cell Dev Biol Anim. 1999; 35(10): 580-592.
[44] Hurst RD, Fritz IB. Properties of an immortalised vascular endothelial/glioma cell co-culture model of the blood-brain barrier. J Cell Physiol. 1996; 167(1): 81-88.
[45] Schroeter ML, Müller S, Lindenau J, Wiesner B, Hanisch UK, Wolf G, Blasig IE. Astrocytes induce manganese superoxide dismutase in brain capillary endothelial cells. Neuroreport. 2001; 12(11): 2513-2517.
[46] Gaillard PJ, van der Sandt IC, Voorwinden LH, Vu D, Nielsen JL, de Boer AG, Breimer DD. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharm Res. 2000; 17(10): 1198 -1205.
[47] Joó F. Endothelial cells of the brain and other organ systems: some similarities and differences. Prog Neurobiol. 1996; 48(3): 255-273.
[48] Franke H, Galla H, Beuckmann CT. Primary cultures of brain microvessel endothelial cells: a valid and flexible model to study drug transport through the blood-brain barrier in vitro. Brain Res Brain Res Protoc. 2000; 5(3): 248 -256.
[49] Godwin HA. The biological chemistry of lead. Curr Opin Chem Biol. 2001;5(2): 223-227.
[50] Greenwood NN, Earnshaw A. Chemistry of the elements. 2nd ed. London: Butterworth-Heinemann. 1997.
[51] Habermann E, Crowell K, Janicki P. Lead and other metals can substitute for Ca2+ in calmodulin. Arch Toxicol. 1983; 54: 61-70.
[52] Simons TJ. The affi nity of human erythrocyte porphobilinogen synthase for Zn2+ and Pb2+. Eur J Biochem. 1995; 234: 178-183.
[53] Kern M, Wisniewski M, Cabell L, Audesirk G. Inorganic lead and calcium interact positively in activation of calmodulin. Neurotoxicology. 2000; 21: 353-363.
[54] Ghering AB, Jenkins LM, Schenck BL, Deo S, Mayer RA, Pikaart MJ, Omichinski JG, Godwin HA. Spectroscopic and functional determination of the interaction of Pb2+ with GATA proteins. J Am Chem Soc. 2005; 127: 3751-3759.
[55] Atkins DS, Basha MR, Zawia NH. Intracellular signaling pathways involved in mediating the effects of lead on the transcription factor Sp1. Int J Dev Neurosci. 2003; 21(5): 235-244.
[56] ReddyG R,Z awiaN H.Lead exposure alters Egr-1 DNA-binding in the neonatal rat brain. Int J Dev Neurosci. 2000; 18(8): 791-795.
[57] Sharma R, Rensing C, Rosen BP, Mitra B. The ATP hydrolytic activity of purified ZntA, a Pb(II)/Cd(II)/Zn(II)-translocating ATPase from Escherichia coli. J Biol Chem. 2000; 275(6): 3873-3878.
[58] Erskine PT, Duke EM, Tickle IJ, Senior NM, Warren MJ, Cooper JB. MAD analyses of yeast 5-aminolaevulinate dehydratase: their use in structure determination and in defining the metal-binding sites. Acta Crystallogr D Biol Crystallogr. 2000; 56(Pt 4): 421-430.
[59] Bouton CM, Frelin LP, Forde CE, Arnold Godwin H, Pevsner J. Synaptotagmin I is a molecular target for lead. J Neurochem. 2001; 76(6): 1724-1735.
[60] Lewit-Bentley A, Réty S. EF-hand calcium-binding proteins. Curr Opin Struct Biol. 2000; 10(6): 637-643.
[61] Benes CH, Wu N, Elia AE, Dharia T, Cantley LC, Soltoff SP. The C2 domain of PKCdelta is a phosphotyrosine binding domain. Cell. 2005; 121(2): 271-280.
[62] Rizo J, Südhof TC. C2-domains, structure and function of a universal Ca2+- binding domain. J Biol Chem. 1998; 273(26): 15879-15882.
[63] Qian Y, Zheng Y, Ramos KS, Tiffany-Castiglioni E. GRP78 compartmentalized redistribution in Pb-treated glia: role of GRP78 in lead-induced oxidative stress. Neurotoxicology. 2005; 26(2): 267-275.
[64] Qian Y, Tiffany-Castiglioni E. Lead-induced endoplasmic reticulum (ER) stress responses in the nervous system. Neurochem Res. 2003; 28(1): 153-162.
[65] Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001; 107(1): 43-54.
[66] Garrick MD, Singleton ST, Vargas F, Kuo HC, Zhao L, Kn?pfel M, Davidson T, Costa M, Paradkar P, Roth JA, Garrick LM. DMT1: which metals does it transport? Biol Res. 2006; 39(1): 79-85.
[67] Adonaylo VN, Oteiza PI. Lead intoxication: antioxidant defenses andoxidative damage in rat brain. Toxicology. 1999; 135(2-3): 77-85.
[68] Flora GJ, Seth PK. Alterations in some membrane properties in rat brain following exposure to lead. Cytobios. 2000; 103(403): 103-109.
[69] Gurer H, Ercal N. Can antioxidants be beneficial in the treatment of lead poisoning? Free Radic Biol Med. 2000 Nov 15; 29(10): 927-945.
[70] Sandhir R, Julka D, Gill KD. Lipoperoxidative damage on lead exposure in rat brain and its implications on membrane bound enzymes. Pharmacol Toxicol. 1994; 74(2): 66-71.
[71] Aykin-Burns N, Franklin EA, Ercal N. Effects of N-acetylcysteine on lead-exposed PC-12 cells. Arch Environ Contam Toxicol. 2005; 49(1): 119-123.
[72] Vaziri ND, Lin CY, Farmand F, Sindhu RK. Superoxide dismutase, catalase, glutathione peroxidase and NADPH oxidase in lead-induced hypertension.Kidney Int. 2003; 63(1): 186-194.
[73] Goyer RA. Transplacental transport of lead. Environ Health Perspest. 1990; 89: 101-105.
[74] 阮素云, 顾祖维, 杨勇骥. 采用能谱法研究铅对大鼠BBB的通透性. 中华预防医学杂志. 1999; 33(2): 107-109.
[75] Wang Q, Luo W, Zheng W, Liu Y, Xu H, Zheng G, Dai Z, Zhang W, Chen Y, Chen J. Iron supplement prevents lead-induced disruption of the blood-brain barrier during rat development. Toxicol appl pharmacol 2007; 219(1): 33-41.
[76] Garza A, Vega R, Soto E. Cellular mechanisms of lead neurotoxicity. Med Sci Monit. 2006; 12(3): RA57-65.
[77] Yan D, Wang L, Ma FL, Deng H, Liu J, Li C, Wang H, Chen J, Tang JL, Ruan DY. Developmental exposure to lead causes inherent changes onvoltage-gated sodium channels in rat hippocampal CA1 neurons. Neuroscience. 2008; [Epub ahead of print].
[78] Soodi M, Sharifzadeh M, Naghdi N, Ostad N, Abdollahi M, Roghani A. Systemic and developmental exposure to lead causes spatial memory deficits and a reduction in COX-2 immunoreactivity in the hippocampus of male rats. J Neurosci Res. 2007; 85(14): 3183-3192.
[79] Gilbert ME, Lasley SM. Developmental lead (Pb) exposure reduces the ability of the NMDA antagonist MK-801 to suppress long-term potentiation (LTP) in the rat dentate gyrus, in vivo. Neurotoxicol Teratol. 2007; 29(3): 385-393.
[80] Gilbert ME, Kelly ME, Samsam TE, Goodman JH. Chronic developmental lead exposure reduces neurogenesis in adult rat hippocampus but does not impair spatial learning. Toxicol Sci. 2005; 86(2): 365-374.
[81] Grandjean P, Landrigan PJ. Developmental neurotoxicity of industrial chemicals. Lancet. 2006 Dec 16;368(9553):2167-78.
[82] Pollitt E. Fuctional significance of the covariance between protein energy malnutrition and iron deficiency anemia. J Nutr. 1995; 125: 2272.
[83] Gerlach, M, Benshachar D, Riederer P, Youdim MB. Altered brain metabolism of iron as a cause of neurodegenerative diseases. J Neurochem. 1994; 63: 793-807.
[84] Qian ZM, Pu YM, Tang PL, Wang Q. Transferrin-bound iron uptake by the cultured cerebellar granule cells. Neurosci Lett. 1998; 251: 9-12.
[85] Beard JL, Chen, Q, Connor J, Jones BC. Altered monamine metabolism in caudate-putamen of iron-deficeint rats. Pharmacol Biochem Behav. 1994; 48: 621-624.
[86] Bartlett WP, Li XS, Connor JR. Expression of transferrin mRNA in theCNS of normal and jimpy mice. J Neurochem. 1991; 57: 318-322.
[87] Taylor EM, Morgan EH. Developmental changes in transferrin and iron uptake by the brain in the rat. Dev Brain Res. 1990; 55: 35 -42.
[88] Connor JR, Boeshore KL, Benkovic SA, Menzies SL. Isoforms of ferritin have a specific cellular distribution in the brain. J Neurosci Res . 1994; 37: 461-465.
[89] Dallman PR, Spirito RA. Brain iron in the rat: extremely slow turnover in normal. rats may explain the long-lasting effects of early iron deficiency. J Nutr. 1977; 107:1075-1081.
[90] Samaniego F, Chin J, Iwai K, Rouault TA, Klausner RD. Molecular characterization of a second iron-responsive element binding protein,iron regulatory protein 2 structure,function,and post-translational regulation. J Biol Chem. 1994; 269(49): 30904.
[91] Guo B, Yu Y, Leibold EA. Iron regulates cytoplasmic levels of a novel iron-responsive element-binding protein without aconitase activity. J. Biol. Chem. 1994; 269: 24252-24260.
[92] Henderson BR, Seiser C, Kuhn LC. Characterization of a second RNA- binding protein in rodents with specificity for iron-responsive elements. J Biol Chem. 1993; 268: 27327-27334.
[93] Samaniego F, Chin J, Iwai K, Rouault TA, Klausner RD. Molecular characterization of a second iron-responsive element binding protein, iron regulatory protein 2. Structure, function, and posttranslational regulation. J Biol Chem. 1994; 269: 30904-30910.
[94] Schalinske KL, Blemings KP, Steffen DW, Chen OS, Eisenstein RS. Iron regulatory protein 1 is not required for the modulation of ferritin and transferrin receptor expression by iron in a murine pro-B lymphocyte cellline. Proc Natl Acad Sci U S A. 1997; 94(20): 10681-10686.
[95] Crichton RR, Wilmet S, Legssyer R, Ward RJ. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J Inorg Biochem. 2002; 91: 9-18.
[96] Goessling LS, Mascotti DP, Thach RE. Involvement of heme in the degradation of iron-regulatory protein 2. J Biol Chem. 1998; 273(20): 12555- 12557.
[97] Ishikawa H, Kato M, Hori H, Ishimori K, Kirisako T, Tokunaga F, Iwai K. Involvement of heme regulatory motif in heme-mediated ubiquitination and degradation of IRP2. Mol Cell. 2005; 19(2): 171-181.
[98] Wang J, Chen G, Muckenthaler M, Galy B, Hentze MW, Pantopoulos K. Iron-mediated degradation of IRP2, an unexpected pathway involving a 2-oxoglutarate-dependent oxygenase activity. Mol Cell Biol. 2004; 24: 954- 965.
[99] Eisenstein RS. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu Rev Nutr. 2000; 20: 627-662.
[100] Haile DJ, Rouault TA, Harford JB, Kennedy MC, Blondin GA, Beinert H, Klausner RD. Cellular regulation of the iron-responsive element binding protein: disassembly of the cubane iron-sulfur cluster results in high-affinity RNA binding. Proc Natl Acad Sci U S A. 1992; 89(24): 11735-11739.
[101] Rouault TA, Haile DJ, Downey WE, Philpott CC, Tang C, Samaniego F, Chin J, Paul I, Orloff D, Harford JB, Klausner RD. An iron-sulfur cluster plays a novel regulatory role in the iron-responsive element binding protein. Biometals. 1992; 5(3): 131-140.
[102] Fillebeen C, Caltagirone A, Martelli A, Moulis JM, Pantopoulos K. IRP1Ser-711 is a phosphorylation site, critical for regulation of RNA-binding and aconitase activities. Biochem J. 2005; 388(Pt 1): 143-150.
[103] Brown NM, Anderson SA, Steffen DW, Carpenter TB, Kennedy MC, Walden WE, Eisenstein RS. Novel role of phosphorylation in Fe-S cluster stability revealed by phosphomimetic mutations at Ser-138 of iron regulatory protein 1. TProc Natl Acad Sci U S A. 1998; 95(26): 15235-15240.
[104] Bannon D I, Portnoy ME, Olivi L, Uptake of lead and iron by divalent metal transporter 1 in yeast and mammalian cells. Biochem Biophys Res Commun. 2002; 295(4): 978-984.
[105] Siddappa AJ, Rao RB, Wobken JD, Casperson K, Leibold EA, Connor JR, Georgieff MK. Iron Deficiency Alters Iron Regulatory Protein and Iron Transport Protein Expression in the Perinatal Rat Brain. Pediatr Res. 2003; 53(5): 800-807.
[106] Chen H, Davidson T, Singleton S, Garrick MD, Costa M. Nickel decreases cellular iron level and converts cytosolic aconitase to iron-regulatory protein 1 in A549 cells. Toxicol Appl Pharmacol. 2005; 206(3): 275-287.
[107] Parton RG, Joggerst B, Simons K. Regulated internalization of caveolae. J Cell Biol. 1994; 127: 1199-1215.
[108] Cordova FM, Rodrigues AL, Giacomelli MB, Oliveira CS, Posser T, Dunkley PR, Leal RB. Lead stimulates ERK1/2 and p38MAPK phosphorylation in the hippocampus of immature rats. Brain Res. 2004; 998(1): 65-72.
[109] Jovanovic JN, Czernik AJ, Fienberg AA, Greengard P, Sihra TS. Synapsins as mediators of BDNF-enhanced neurotransmitter release. Nat Neurosci. 2000; 3: 323-329.
[110] Matsubara M, Kusubata M, Ishiguro K, Uchida T, Titani K, Taniguchi H. Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions. J Biol Chem. 1996; 271(35): 21108-21113.
[111] Bhat RV, Engber TM, Finn JP, Koury EJ, Contreras PC, Miller MS, Dionne CA, Walton KM. Region-specific targets of p42/p44 MAPK signaling in rat brain. J Neurochem. 1998; 70: 558-571.
[112] Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. J Neurochem, 2000, 74: 1587-1595.
[113] Atkins CM, Yon M, Groome NP, Sweatt JD. Regulation of myelin basic protein phosphorylation by mitogen-activated protein kinase during increased action potential firing in the hippocampus. J Neurochem. 1999; 73(3): 1090-1097.
[114] Basuroy S, Seth A, Elias B, Naren AP, Rao R. MAP kinase interacts with occludin and mediates EGF-induced prevention of tight junction disruption by hydrogen peroxide. Biochem J. 2006; 393: 69-77.
[115] 黄强. 胶质瘤. 第二版. 北京: 中国科学技术出版社. 2000. 84.
[116] Reiche1 A, Begley DJ, Abboet NT. An overview of in vitro techniques for BBB studies in nagsed the BBB biology and research. Protocols Humana press. New Jersey. 2003, 307-324.
[117] Gee JR, Keller JN. Astrocys: regulation of brain homeostasis via apolipoprotein E. Int J Biochem Cell Biol. 2005; 37(6): 1145-1150.
[118] Willis LL, Nolan LL, Reith SN. Focal astrocyte loss is followed bymicrovascular damage, with subsequent repair of the BBB in the apparent absence of direct astrocytic contact. Glia. 2004; 45(4): 325-337.
[119] Hamms S, Dehouck B, Kraus J. Astrocyte mediated modulation of BBB permeability dose not correlate with a loss of TJ proteins from the cellular contacts. Cell Tissue Res. 2004; 315(2): 157-166.
[120] Tahti H, Nevala H, Toimela T. Astrocyte and endothelial three-dimensional refining in vitro neurotoxicity testing-the development of BBB models. Altern Lab Anim. 2003; 31(3): 273-276.
[121] Jeliazkova-Mecheva VV, Bobilya DJ. A porcine astrocyte/endothelial cell co-culture model of the BBB. Brain Res Protoc. 2003; 12(2): 9-18.
[122] Kido Y, Tamai I, Nakanish T. Evaluation of BBB transporter by co-culture of brain capillary endothelial cells with astrocyte. Metab Pharmacokinee. 2002; 17(1): 34-41.
[123] Schiera G, Sala S, Gallo A, Raffa MP, Pitarresi GL, Savettieri G, Di Liegro I. Permeability properties of a three-cell type in vitro model of BBB. J Cell Mol Med. 2005; 9(2): 373-379.
[124] Fitsanakis VA, Piccola G, Aschner JL. Manganese transport by rat brain endothelial cell-based transwell model in the presence of astrocyte conditioned media. J Neurosci Res. 2005; 15(2): 235-243.
[125] Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: overview: structure, regulation and clinical implications. Neurobiol Dis. 2004; 16(1): 1-13.
[126] Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat. 2002; 200: 629-638.
[127] Ma SH, Lepak LA, Hussain RJ, Shain W, Shuler ML. An endothelial and astrocyte co-culture model of the blood-brain barrier utilizing an ultra-thin,nanofabricated silicon nitride membrane. Lab Chip. 2005; 5(1): 74-85.
[128] Struzynska L, Walski M, Gadamski R, Dabrowska-Bouta B, Rafalowska U. Lead-induced abnormalities in blood–brain barrier permeability in experimental chronic toxicity. Mol Chem Neuropathol. 1997; 31: 207-224.
[129] Hossain MA, Russell JC, Miknyoczki S, Ruggeri B, Lal B, Laterra J.Vascular endothelial growth factor mediates vasogenic edema in acute lead encephalopathy. Ann Neurol. 2004; 55(5): 660-667.
[130] Dingwall-Fordyce I, Lane RE. A follow-up study of lead workers. Br J Ind Med. 1963; 20: 313.
[131] Dill KA. Dominant forces in protein folding. Biochemistry. 1990, 29(31): 7133-7155.
[132] Goto Y, Hagihara Y, Hamada D, Hoshino M, Nishii I. Acid-induced unfolding and refolding transitions of cytochrome c: a three-state mechanism in H2O and D2O. Biochemistry. 1993; 32(44): 11878-11885.
[133] 张培林. 神经解剖学[M]. 北京: 人民卫生出版社. 1995; 506-510.
[134] Mims MP, Prchal JT. Divalent metal transporter 1. Hematology. 2005; 10(4): 339-345.
[135] Mckie AT, Barrow D, Latunde-Dada GO, et al. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science. 2001; 291(5509): 1755-1759.
[136] Zheng W, Perry DF, Nelson DL, Aposhian HV. Protection of cerebrospinal fluid against toxic metals by the choroid plexus. FASEB J. 1991;5: 2188- 2193.
[137] Muldoon SB, Cauley JA, Kuller LH, Morrow L, Needleman HL, Scott J, Hooper FJ. Effects of blood lead levels on cognitive function of older women. Neuroepidemiology. 1996; 15: 62-72.
[138] Schwartz BS, Stewart WF, Bolla KI, Simon PD, Bandeen-Roche K, Gordon PB, Links JM, Todd AC. Past adult lead exposure is associated with longitudinal decline in cognitive function. Neurology. 2000; 55: 1144-1150.
[139] Stollery BT. Reaction time changes in workers exposed to lead. Neurotoxicol Teratol. 1996; 18: 477-483.
[140] Dyatlov VA, Platoshin AV, Lawrence DA, Carpenter DO. Lead potentiates cytokine- and glutamate-mediated increases in permeability of the blood-brain barrier. Neurotoxicology. 1998; 19: 283-291.
[141] Sundstrom R, Muntzing K, Kalimo H, Sourander P. Changes in the integrity of the blood-brain barrier in suckling rats with low dose lead encephalopathy. Acta Neuropathol. 1985; 68: 1-9.
[142] Bradbury MW, Deane R. Permeability of the blood-brain barrier to lead. Neurotoxicol. 1993; 14: 131-136.
[143] Kerper LE, Hinkle PM. Lead uptake in brain capillary endothelial cells: activation by calcium store depletion. Toxicol Appl Pharmacol. 1997; 146: 127-133.
[144] Press MF. Lead-induced permeability changes in immature vessels of the developing cerebellar microcirculation. Acta. Neuropathol. 1985; 67: 86-95.
[145] Press MF. Lead encephalopathy in neonatal Long-Evans rats: morphologic studies. J Neuropathol Exp Neurol. 1977; 36: 169-193.
[146] Nusrat A, Parkos CA, Verkade P, Foley CS, Liang TW, Innis-Whitehouse W, Eastburn KK, Madara JL. Tight junctions are membrane microdomains. J Cell Sci. 2000; 113 ( Pt 10): 1771-1781.
[147] Witt KA, Mark KS, Hom S, Davis TP. Effects of hypoxia-reoxygenation on rat blood-brain barrier permeability and tight junctional protein expression.Am J Physiol Heart Circ Physiol. 2003; 285(6): H2820-2831.
[148] Shi LZ, Zheng W. Early lead exposure increases the leakage of the blood-erebrospinal fluid barrier, in vitro. Hum Exp Toxicol. 2007; 26: 159-167.
[149] Shindo M, Torimoto Y, Saito H, et al. Functional role of DMT1 in transferring-dependent iron uptake by human hepatocyte and hepatocellular carcinoma cell, HLF. Hepatol Res. 2006; 35(3): 152-162.
[150] Roth JA, Horbinski C, Feng L, Dolan KG, Higgins D, Garrick MD. Roth JA, Orbinski C, Feng L, et al. Differential localization of divalent metal transporter 1 with and without iron response element in rat PC12 and sympathetic neuronal cells. Neuroscience. 2000; 20(20): 7595-7601.
[151] Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, Hediger MA. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature. 1997; 388(6641): 482-488.
[152] Ke Y, Chang YZ, Duan XL, et al. Age-dependent and iron-independent expression of two mRNA isoforms of divalent metal transporter 1 in rat brain. Neurobiol Aging. 2005; 26(5): 739-748.
[153] Arredondo M, Mu?oz P, Mura CV, Nù?ez MT. DMT1, a physiologically relevant apical Cu1+ transporter of intestinal cells. Am J Physiol Cell Physiol. 2003; 284(6): C1525-1530.
[154] Ong WY, He X, Chua LH, Ong CN. Increased uptake of divalent metals lead and cadmium into the brain after kainite-induced neuronal injury. Exp Brain Res. 2006; 173(3): 468-474.
[155] Kwong WT, Friello P, Semba RD. Interactions between iron deficiency and lead poisoning: epidemiology and pathogenesis. Sci Total Environ. 2004;330(1-3): 21-37.
[156] Pi?ero DJ, Li N, Hu J, Beard JL, Connor JR. The intracellular location of iron regulatory proteins is altered as a function of iron status in cell cultures and rat brain. J Nutr. 2001; 131(11): 2831-2836.
[157] Tong WH, Rouault T. Distinct iron-sulfur cluster assembly complexes exist in the cytosol and mitochondria of human cells. EMBO J. 2000; 19(21): 5692-5700.
[158] Roy A, Solodovnikova N, Nicholson T, Antholine W, Walden WE. A novel eukaryotic factor for cytosolic Fe-S cluster assembly. EMBO J. 2003; 22(18): 4826-4835.
[159] Wang Q, Luo W, Zhang W, Dai Z, Chen Y, Chen J. Iron supplementation protects against lead-induced apoptosis through MAPK pathway in weanling rat cortex. Neurotoxicology. 2007; 28(4): 850-859.
[160] Eisenstein RS, Tuazon PT, Schalinske KL, Anderson SA, Traugh JA. Iron-responsive element-binding protein. Phosphorylation by protein kinase C. J Biol Chem. 1993; 268(36): 27363-27370.
[161] Schalinske KL, Eisenstein RS. Phosphorylation and activation of both iron regulatory proteins 1 and 2 in HL-60 cells. J Biol Chem. 1996; 271(12): 7168-7176.
[162] Patton SM, Pi?ero DJ, Surguladze N, Beard J, Connor JR. Subcellular localization of iron regulatory proteins to Golgi and ER membranes. J Cell Sci. 2005; 118(Pt 19): 4365-4373.